The frequencies of four different $\beta$ thalassaemia alleles in a Brazilian population.

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Type</th>
<th>No of chromosomes</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) CD 39 (C-T)</td>
<td>$\beta^+$</td>
<td>45</td>
<td>64.3</td>
</tr>
<tr>
<td>(2) IVS-1 110 (G-A)</td>
<td>$\beta^+$</td>
<td>14</td>
<td>20.0</td>
</tr>
<tr>
<td>(3) IVS-1 6 (T-C)</td>
<td>$\beta^-$</td>
<td>5</td>
<td>7.1</td>
</tr>
<tr>
<td>(4) IVS-1 1 (G-A)</td>
<td>$\beta^+$</td>
<td>4</td>
<td>5.7</td>
</tr>
<tr>
<td>(5) Unknown</td>
<td></td>
<td>2</td>
<td>2.9</td>
</tr>
</tbody>
</table>

results, the four most common alleles account for 97.1% of the disease alleles in Brazil. Two mutations, namely the nonsense mutation at codon 39 (C→T) and the IVS-1-nt 110 C→A, account for 84.3% of the thalassaemia alleles. Although approximately 31 thalassaemia mutations have been reported in Mediterranean populations, the allele frequencies vary greatly from one country to another. Comparison of our data on the frequencies of $\beta$ thalassaemia alleles with other Mediterranean populations shows a close similarity between the allele distribution in south-eastern Brazil and northern Italy, mainly the regions of Milan and Lombardia. This was to be expected based on the origin of the Italian immigrants of Mediterranean origin. Most of them originated from northern Italy (Veneto, Piemonte, Lombardia, and Emigilia Romagna) and to a lesser extent from southern Italy (Campania and Calabria). Interestingly, the frequencies of different mutations reported among thalassaemia heterozygotes from central Portugal, where the IVS-1-nt 6 and IVS-1-nt 1 mutations reach high frequencies, are different from those observed in our study. In conclusion, the results presented here indicate that most of the thalassaemia genes in Brazil originated from Italian immigrants and a limited spectrum of mutation is found. They enable us to design a simple and accurate approach to prenatal diagnosis of $\beta$ thalassaemia in the country.

This study was supported in part by grants from FAPESP-Brazil.

3 Costa FF, Taella MA, Zago MA. Molecular bases of $\beta$-thalassaemia in Brazil. Blood 1990;76:586A.

Autozygosity mapping, complex consanguinity, and autosomal recessive disorders

Mapping of autosomal recessive disorders is more problematical than for autosomal dominant or X linked disorders. Many autosomal recessive disorders are individually rare, making it difficult to collect sufficient numbers unless this is done on an international collaborative basis. In addition, in most parts of the world family sizes are limited, with it being uncommon for families to have more than three or four children and therefore making it unusual for there to be more than two affected siblings within a sibship.

Mathematical analysis of the power of nuclear families with autosomal recessive disorders has shown that in order to have a high likelihood of showing linkage in gene mapping studies, inordinate numbers of families, preferably with multiple affected siblings, are required as described by Wong et al.

Use of homozygosity mapping with affected offspring of first cousins has been advocated as far fewer families are needed to have the same likelihood of showing linkage, an approach originally suggested by Smith and more recently by Lander and Botstein. Morton has reminded us that this approach is more correctly called autozygosity mapping.

An estimate of the lod score under complete linkage to determine rapidly the potential usefulness of various consanguinous pedigrees for a single affected offspring can be derived by the use of the formula:

$$\text{Elod} = \log_{10} \left[ \frac{qF^2 + (1 - Fq)^2}{(qF^2 + (1 - Fq)^2)(pF^2 + (1 - Fp)^2)} \right]$$

Figure 1: Effect on the lod score under complete linkage (0=0) of the disease allele (q) and marker allele (r) for an affected offspring of first cousins.

The effect of variation in the disease allele frequency (q), the marker allele frequency (r) will affect the power of this approach in individual pedigrees (fig 1).

Detailed enquiry into the family history of affected offspring of ostensible first cousin matings from ethnic groups in which consanguineous marriage is common usually shows the consanguinity to be much more complex than at first enquiry. In addition, ostensibly unrelated affected subjects from that population are often found to be related but in different sibships within the same pedigrees. Efficient use of linkage information from such complex consanguineous families requires conventional linkage analysis.

When pooling linkage information from different complex consanguineous families, the possibility of genetic heterogeneity must be considered. It is likely, however, that a limited number of genes will be responsible for a particular autosomal recessive disorder in an individual isolated population in which complex consanguinity is common.

In populations in which consanguineous marriage is common, it has often been the usual pattern of marriage for a number of generations. It has been argued that long term inbreeding will reduce the power of this approach. Two factors will affect the usefulness of this approach in this situation. Prior or remote long term inbreeding (Fp) combines with the 'bottleneck' of close inbreeding (F) for a particular pedigree as Fp (1 - F), which essentially reduces to Fp + F. The effect of substituting this in the above formula is to increase the apparent power of this approach. Another consequence of long term prior inbreeding is to 'redistribute' the disease and marker alleles with a reduction in the proportion of the two homozygotes in the population. The effect of this can be

![Figure 2: Effect of various prior inbreeding coefficients of the population (Fp) at q=0 on the lod score for a single affected offspring of first cousins for marker allele frequency (r) and disease allele frequency q=0.02.](http://jmg.bmj.com/)

J Med Genet: first published as 10.1136/jmg.30.9.798 on 1 September 1993. Downloaded from http://jmg.bmj.com/ on July 14, 2023 by guest. Protected by copyright.
corrected for by substituting $q^r$ for $q$ and $r^w$ for $r$ similarly in the formula above where:

$$q^r = q + Fr(1 - q)$$

and $F^w$ equals the coefficient of inbreeding of the population owing to prior inbreeding. The overall effect modelling for both of these effects reduces, to some extent, the power of this approach (fig 2).

Values for the long term background coefficient of inbreeding in populations in which complex consanguinity is common will need to be determined before using such families in linkage studies.

R F MUELLER
Department of Clinical Genetics, Ashley Wing, St James's Hospital, Beckett Street, Leeds LS9 7TF, UK.

D T BISHOP
Imperial Cancer Research Fund Genetic Epidemiology Laboratory, Ashley Wing, St James's Hospital, Beckett Street, Leeds LS9 7TF, UK.


BOOK REVIEWS

If you wish to order or require further information regarding any book reviewed here, please write to or telephone the BMJ Bookshop, PO Box 295, London WC1H 9JR. Tel 071 383 6244. Fax 071 383 6662. Books are supplied post free in the UK and for BFPO addresses. Overseas customers should add 15% for postage and packing. Payment can be made by cheque in sterling drawn on a UK bank or by credit card (Mastercard, Visa, or American Express) stating card number, expiry date, and full name. (The price and availability are occasionally subject to revision by the Publishers.)


These proceedings are the eleventh from the International Histocompatibility Workshop (IHW) community in a history of almost 30 years; they are dedicated to the memories of the late Hilliard Festenstein and Fleming Kissmyer-Nielsen. Anyone wishing to keep abreast of developments in definition of the human Mhc, its alleles, and clinically relevant products will find these volumes essential reading and reference. This review of such a significant publication is best restricted to highlighting the contents as a 'must read' to anyone contemplating the cost of £175.

Volume 1 contains the 11th IHW report and data analyses with an overview and WHO Nomenclature Committee report listing the newly accepted alleles, specificities, and genes as part of HLA. This IHW may be the last to have a complete serological component and the antigen society reports are the key reference for laboratories using serology to define HLA-A,B,Cw, and DQ specificities. Although monoclonal antibodies to HLA specificities have not replaced the use of alloantiserums for routine typing they were used in IHW studies to define new specificities and could detect sequence polymorphisms and specific epitopes such as the definition of HLA-DR103, to which alloanti- sers do not exist. The use of HLA transfants for generation of monoclonal antibodies resulted in studies of eight HLA class I and 13 HLA class II specific polymorphisms.

The most valuable aspect of the 'DNA component' report is the wide range of techniques documented for anyone to try. The 11th IHW protocols are inevitably already dated with the sequencing of many more HLA-DR and -DP alleles in the last 12 months.

A major objective of the IHW was the documentation of HLA, alleles, and specificities in different populations. This was achieved with some success and specific reports are included. The reference tables (155 pages) contain masses of data which are valuable to both researchers and routine histocompatibility testers.

Studies of HLA and disease associations now concentrate on defining specific susceptibility epitopes or functional relationships between specificities and infectious agents; the latter is best illustrated by HLA-B53 positivity in malaria patients reviewed in volume 2. Some 19 diseases were examined by serological and molecular techniques; there were those with established HLA associations (IDDM, RA, IMN, CD, etc) and new studies such as that of HIV. In the latter multicentre European study, 271 HIV positive persons showed no significant HLA association and the report concludes 'the analysis does not provide much evidence that susceptibility to become infected with HIV or to develop AIDS is controlled by the HLA system'. Some of the disease studies are more comprehensive than others with the RA study being insufficient.

Unfortunately the studies of HLA and organ transplantation were rather restricted in this IHW and suffered from world wide organisational difficulties. This is disappointing given that recent studies continue to emphasise the imperative for HLA matching in narrow transplantation and the advantages of outcome in HLA matched solid organ transplants. The HLA community must not forget that much of the drive to elucidate this gene complex came from the need to apply the knowledge gained to clinical transplantation.

The technique of immunoprecipitation of metabolically labelled HLA molecules followed by isoelectric focusing is established in the preparation of specific HLA antibodies. Notably, mixed lymphocyte culture assays and their associated complex data were not included in this IHW.

Other core IHW studies included C4, C2, and Bf complement genes which are encoded in the HLA-A/B/DR region: studies on human reproductive failure in 402 cases world wide of habitual abortive couples which showed no significant role for HLA genes, and studies of serum soluble HLA class I and II.

Volume 2 of HLA 1991 has 122 pages of invited overviews and 531 pages of papers presented at the IHW Conference. The overviews are essential reading for state of the art information on HLA and are varied from HLA genetics, antigen presentation, gene regulation, disease associations and clinical applications to evolutionary mechanisms. These areas and others are expanded in the themes of contributed papers; the section on molecular typing methodology is particularly thought provoking.

Volume 2 contains 33 pages of IHW participants names and addresses; this is most useful but inclusion of fax numbers would have been a great help in contacting this worldwide community.

At first glance the two volumes of HLA 1991 appear forbidding. Do not be put off! They are easy to 'get around' and follow a logical structure. The larger of the books, volume 1, contains the data needed for reference and will stay on the desk or in the laboratory while volume 2 can be carried home for digestion. The tradition of the IHWs is carried forward in these books and these are milestones such as protein frequency data and methodology which will make them a continued reference. No HLA researcher or histocompatibility tester can be without them particularly since it is planned.